Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|September 14, 2020
Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapyJohannes Stelwagen, Sjoukje Lubberts, Lars C Steggink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular CancerJoost M Blok, Harmke J Groot, Eline H Huele, et al.
Current Oncology (Toronto, Ont.)|August 25, 2022
Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA StudyCarla Vlooswijk, Lonneke V van de Poll-Franse, Silvie H M Janssen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 13, 2024
Exploring the interconnectedness between health-related quality of life factors among long-term adolescent and young adult cancer survivors (AYAs): a network analysisTom I Bootsma, Deborah van de Wal, Carla Vlooswijk, et al.
Cancers|November 27, 2021
Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after TreatmentJohannes Stelwagen, Andrea T Meuleman, Sjoukje Lubberts, et al.
Psycho-Oncology|November 22, 2025
Health-Related Quality of Life in Adolescents and Young Adults With an Uncertain or Poor Cancer Prognosis: Quantitative Baseline Results of the CORD-AYA StudyMilou J P Reuvers, Helle-Brit Fiebrich-Westra, Johan A F Koekkoek, et al.
European Journal of Endocrinology|March 19, 2025
Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization GroupSelina R van den Oever, Renée L Mulder, Kevin C Oeffinger, et al.
The Lancet. Oncology|June 29, 2026
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialRianne L Seefat, Sonja B Vliek, Vincent M T de Jong, et al.
Pageof 5